Published in final edited form as:

Tumori. 2009 ; 95(6): 753–761.

DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study

Ikuko Kato^{1,2}, Kawsar Z Badsha³, Susan Land^{1,4}, Jordan M Nechvatal⁵, Larry H Matherly^{1,6},
Adi L Tarca^{1,7}, Adhip P Majumdar^{1,8}, Marc D Basson^{1,9,10}, and Jeffrey L Ram⁵

¹Karmanos Cancer Institute, Wayne State University, Detroit, MI

²Department of Pathology, Wayne State University, Detroit, MI

³Department of Nutrition and Food Science, Wayne State University, Detroit, MI

⁴Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI

⁵Department of Physiology, Wayne State University, Detroit, MI

⁶Department of Pharmacology, Wayne State University, Detroit, MI

⁷Department of Computer Science, Wayne State University, Detroit, MI

⁸Department of Internal Medicine, Wayne State University, Detroit, MI

⁹Department of Surgery, Wayne State University, Detroit, MI

¹⁰Surgical Service, John D Dingell VA Medical Center, Detroit, MI, USA

Abstract

Aims and background—Exfoliated cells in human stool offer excellent opportunities to non-invasively detect molecular markers associated with colorectal tumorigenesis, and to evaluate the effects of exposures to exogenous and endogenous carcinogenic or chemopreventive substances. This pilot study investigated the feasibility of determining DNA methylation and RNA expression simultaneously in stool specimens treated with a single type of nucleic acid preservatives.

Methods—Stool specimens from 56 volunteers that were preserved up to a week with RNAlater were used in this study. Bisulfite sequencing was used to determine methylation at 27 CpG loci on the estrogen receptor 1 (*ESR1*) promoter. Taqman assay was used for quantitative reverse transcription polymerase chain reactions to measure cyclooxygenase 2 (*COX2*) and epidermal growth factor receptor (*EGFR*) mRNA expression. Subjects' basic demographic and other selected risk factors for colorectal cancer were captured through questionnaires and correlated with the levels of these markers.

Results—Less than 10% of the samples failed in individual assays. Overall, 24.0% of the CpG loci on the *ESR1* promoter were methylated. *COX2* expression and alcohol use were positively correlated; an inverse association was present between *EGFR* expression and cigarette smoking; and subjects using anti-diabetic medication had higher *ESR1* methylation. In addition, higher

EGFR expression levels were marginally associated with history of polyps and family history of colorectal cancer.

Conclusions—The present study demonstrates that simultaneous analyses for DNA and RNA markers are feasible in stool samples treated with a single type of nucleotide preservatives. Among several associations observed, the association between *EGFR* expression and polyps deserves further investigation as a potential target for colorectal cancer screening. Larger studies are warranted to confirm some of our observations.

Keywords

stool test; DNA; RNA; colorectal cancer

Introduction

It has been estimated that approximately 1.5 million human colonic epithelial cells can be isolated per gram of human stool^{1,2}. Thus, exfoliated cells in stool offer excellent opportunities to non-invasively detect molecular markers associated with colorectal tumorigenesis, as well as to evaluate the effects of luminal and systemic exposures of colorectal epithelial cells to exogenous and endogenous carcinogenic or chemopreventive substances^{3,4}.

Most stool-based screening tests for molecular markers utilize fresh or frozen stool specimens. This requires prompt transfer of sample from the subject's home to a testing laboratory, which may not always be practical. However, new technologies have recently become available to preserve DNA and RNA for a period of time at room temperature, so that immediate processing is no longer necessary^{5,6}. Such technologies may greatly facilitate screening tests and epidemiological studies. In fact, mutations, microsatellite instability, and aberrant promoter methylation in several candidate genes have already been introduced in colorectal cancer screening^{3,7,8}. In addition, methylation in other genes, including the estrogen receptor 1 (*ESR1*), are suggested to serve as a marker for both aging and colorectal cancer⁹. A number of genes that are overexpressed in colorectal cancer tissue also represent potential targets for new therapy and RNA-based screening. Of particular interest are cyclooxygenase 2 (*COX2*), which has already been tested in several studies for screening^{8,10}, and epidermal growth factor receptor (*EGFR*), for which an anti-EGFR therapy has been approved by the FDA for advanced colorectal cancer¹¹. Importantly, aberrant promoter methylation and *COX2* and *EGFR* expressions have been shown to be influenced by environmental factors¹²⁻¹⁶ that are associated with increased risk of colorectal cancer, e.g., alcohol intake¹⁷ and cigarette smoking^{18,19}, as well as with reduced risk, such as aspirin and non-steroidal anti-inflammatory drug use²⁰.

Although some clinical studies have employed DNA preservatives for stool testing^{7,21-23}, media that can preserve both DNA and RNA are highly desirable in order to examine different types of markers simultaneously. Despite the perceived difficulty in recovering good quality RNA from stool samples, our laboratory recently reported the use of commercially available preservatives that enabled analysis of mRNA for a specific gene in most stool samples tested⁵. In that study, we compared comprehensively several

commercially available preservatives in both DNA and RNA quantity and quality as well as in PCR inhibitory effects in order to choose one that works best for downstream DNA and mRNA analyses^{5,6}. The aims of this cross-sectional study were (i) to test the feasibility of a selected preservative, RNAlater, to quantify fecal *ESR1* promoter methylation and *EGFR* and *COX2* mRNA expression; and (ii) to examine whether these molecular markers were affected by age, gender, alcohol intake, cigarette smoking, regular aspirin use, colorectal polyp history, and family history of colorectal cancer.

Materials and methods

Study subjects

The subjects included in this study were individuals aged 48 or older or those younger than 48 with a history of polyps. Ineligibility criteria included recent use (within a month) of oral antibiotics (due to their effects on intestinal bacteria) or medications known to affect methylation (including some antineoplastic, antirheumatic, and anti-AIDS agents such as 5-FU derivatives, methotrexate, sulfasalazine, and AZT, and other medications, such as hydralazine and procainamide), recent history of an infectious type of diarrhea, or a history of major colorectal surgery (i.e., hemicolectomy or total colectomy). Those with a history of colorectal cancer were also ineligible for this study. The study comprised 2 phases: the initial phase for the development and validation of fecal specimen collection, processing, and stool marker assays, and the second phase for application of a single selected stool collection/processing method to community volunteers. The first phase involved 10 patients being evaluated at a vascular clinic, the John D. Dingell VA Medical Center (Detroit, MI), that have been described in more detail elsewhere⁶; the second phase involved 53 community volunteers who were recruited through flyers and personal referral. Among the 63 study subjects, 12 reported a previous diagnosis of colorectal polyps. The research protocol was approved by the human investigation committees of the Wayne State University and the VA Medical Center, and signed informed consent was obtained from each study participant.

Sample collection and processing

The sample collection and processing procedures for the initial phase have been described previously^{5,6}. Briefly, fresh stool samples were collected and tested after storage with several commercially available preservatives for 5 days, in comparison with stool samples immediately frozen in liquid nitrogen. Based on these results, we chose RNAlater (Ambion, Austin, TX, USA) as the preservative to be used in the second phase. Although RNAlater is a non-toxic chemical, it is an irritant. Thus, to minimize the risk of accidental exposure for prospective participants, we invented a special fume-free device that enabled subjects to mix a stool aliquot with the solution without contacting or inhaling the chemical (International Patent Appln. No. PCT/US 08/1089). The device contains 5 mL of RNAlater solution, and a collection spoon with an ejectable tip to hold an approximately 0.2 g stool aliquot. Two kits were provided to each participant with instructions for sending collected samples back to our laboratory by priority mail in leak-free plastic bags in an envelope that we provided. Upon receipt, samples were centrifuged, and pellets were transferred to -80 °C. For each subject, total RNA was extracted from 1 of the 2 samples using the RNA PowerSoil™ (MO BIO

Laboratories, Carlsbad, CA, USA) method, and DNA was extracted by a Qiagen Stool kit (Qiagen, Hilden, Germany) from the second sample, except in the case of 1 participant from whom only 1 satisfactory sample was received which was processed for RNA only. All extraction procedures followed original manufacturers' standard procedures for RNA and human DNA extraction.

Data concerning subjects' medical history, family history, smoking, drinking, body weight and height were obtained through structured questionnaires. All subjects in phase 1, and 8 subjects in phase 2 were interviewed in person to complete the questionnaires. Nine subjects in phase 2 were interviewed over the telephone, while the remainder of the subjects in phase 2 chose to complete the questionnaires by themselves at home and to return them by mail. The information about subjects' characteristics were not shared with laboratory personnel who performed the assays to ensure unbiased assessments.

DNA methylation assays

DNA (2 µg) was denatured in 0.3 M NaOH, treated with 3 M sodium metabisulfite and 0.5 M hydroquinone for 20 heating cycles (95 °C 30 s alternating with 50 °C 15 min), then purified, desulfonated, and precipitated in 40 mM sodium acetate in 96% ethanol at -80 °C. In order to increase specificity and sufficient amplification of this human DNA target, we used nested PCR to amplify the 5'-untranslated region at bases -247 to -1 upstream from the ATG start codon of *ESR1*, which contained 27 CpG sites (Figure 1A). Primers in the first-round amplification were LP-ER-403 (5'-GAG-TGA-TGT-TTA-AGT-TAA-TGT-TAG-GGT-AAG-3') and RP-ER-403 (5'-ATC-TAA-TAC-AAT-AAA-ACC-AC-CCA-AAT-ACT-3'), and those in the second round were LP-ER-290 (5'-GAG-ATT-AGT-ATT-TAA-AGT-TGG-AGG-TT-3') and RP-ER-290 (5'-AAT-ATA-AAA-AAT-CAT-AAT-CAT-AAT-CC-3'). Purified bisulfite-treated DNA or PCR product from the preceding round was amplified using 10 pmol each of primers, 2.5 U Taq DNA polymerase, 1.25 mM MgCl₂, dNTPs and PCR buffer (Applied Biosystems) in a final volume of 50 µL. The first-round PCR thermocycle consisted of 93 °C for 3 min initial denaturation, 40 cycles of amplification (45 s 93 °C, 45 s 55 °C primer annealing, 1 min 72 °C elongation), and 7 min final 72 °C elongation. Second-round PCR was identical except that the annealing step was at 50 °C.

The PCR products were separated on 1.5% agarose gels, purified with a Rapid Gel Extraction System[®] (Marligen Biosciences, Inc, Rockville, MD, USA), and then cloned for sequencing using the TOPO TA Cloning[®] kit (Invitrogen, Carlsbad, CA, USA). Two clones were analyzed for each sample. After confirming the presence of the target DNA region in each amplicon by reamplification, DNA was purified and sequenced. The presence of methylation at each of the 27 CpG sites was determined by comparing the resultant sequences with the reference human genomic sequence, scoring sites as methylated or non-methylated according to the presence of C or T, respectively. DNA extracted from MCF-7 and SW-48 cell lines were used as negative and positive controls.

Quantitative reverse transcription polymerase chain reactions (qRT-PCR)

The expression levels of 3 genes were quantified by qRT-PCR in 3 samples from the first phase and 28 from the second phase that had at least 0.5 µg of total RNA left (n = 31). This reduction in the sample size was partly due to heavy usage of some of the samples (particularly those in phase 1) for other purposes. cDNA was prepared from total RNA isolated from stool using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). The cDNA was preamplified using the TaqMan PreAmp Master Mix Kit with pooled TaqMan assay mixes for *PTGS2*, *EGFR*, and *RPLP0* (the gene for protein P0 of the large ribosomal subunit, considered a housekeeping gene for internal reference control), for 10 cycles. Expression analysis for *PTGS2*, *EGFR*, and *RPLP0* were run using TaqMan assay mixes. The assays were run in triplicate at 3 concentrations (1:5, 1:10 and 1:20 dilution) with no template controls on an AB7900. PCR efficiencies for each primer set were assessed by changes in threshold cycle numbers by 2-fold dilution specified above. The mean change by dilution was almost identical for the 3 genes, 1.0349 for *EGFR*, 0.9968 for *COX2*, and 1.0987 for *RPLP0*, and little different from the expected value, 1.000. All reactions were run with standard conditions as per manufacturers' protocols.

Statistical analysis

Descriptive statistics were presented for each stool marker after averaging 2 methylation frequencies from bisulfite sequencing and 9 repeated measures (triplicate assays at the 3 concentrations) for Ct values. Relative quantification of gene expression was performed by computing the difference in PCR threshold cycle numbers (Ct values) between *RPLP0* and the target genes (*PTGS2* and *EGFR*). Levels of each marker were then categorized into 3 levels (approximate tertiles); negative, low and high, based on the overall distribution. The prevalence (%) of the selected characteristics of the study subjects was calculated by the level of each stool marker and the distributions of these characteristics by stool marker level were tested by Fisher's exact test. In addition, if the selected characteristics were originally given as continuous values, Spearman's correlation co-efficients between the stool markers and those covariates were calculated. All *P* values were 2 sided.

Results

Among the 52 samples tested for *ESR1* methylation, 3 failed to amplify the *ESR1* gene after bisulfite treatment, and 2 of the 31 RNA samples tested failed to amplify *RPLP0*. Thus, the effective sample size was 49 for DNA methylation, and 29 for RNA expression assay (Table 1). Altogether, there were 55 study subjects aged 27-73 years (median 60 years) including 10 with a history of polyps. For the bisulfite sequencing analysis of *ESR1* methylation, a total of 2,646 loci were sequenced for the 49 subjects, and 634 (24.0%) were found to be methylated. A high intra-individual (clone) correlation was present among methylated loci, i.e., methylation clustered within individuals/clones (Figure 1B). The median number of methylated CpG sites out of the 27 tested for each subject was 1.5, while 9 subjects had average values of 20 or above. *EGFR* transcript levels were higher than those of *RPLP0* for most of the RNA samples. *COX2* was expressed in approximately two-thirds of the samples, and the median expression level was lower than that of *RPLP0* (Table 1).

Tables 2-4 present the associations between these molecular markers and subjects' characteristics. For *ESR1* methylation (Table 2), the average number of methylated CpG islands out of the 27 loci were grouped as follows; negative: 0 and 0.5 (borderline positive), low: 1-9.5 loci, and high: equal or above 10 loci. There were no subjects whose samples yielded values between 6.5 and 10. Participants' demographics, history of polyps or family history of colorectal cancer were not associated with the level of *ESR1* methylation.

For *EGFR* (Table 3), the expression levels were grouped into those less than *RPLP0*, those 0 to 1.5 Ct units greater than *RPLP0*, and those more than 1.5 Ct units greater than *RPLP0*. 1.5 Ct units change may be interpreted as ~2.82 fold change when PCR efficiencies are exactly the same for a target and a reference gene. The proportion of subjects who had ever smoked tended to decrease with *EGFR* expression levels, and the correlation between *EGFR* expression levels and the number of pack-years of cigarette smoking was statistically significant ($P=0.046$). In addition, we observed marginally significant associations between higher expression levels and history of polyps ($P=0.050$) and family history of colorectal cancer ($P=0.089$).

The proportion of subjects who consumed at least 1 alcoholic drink per day tended to be higher in subjects expressing *COX2*, particularly in subjects whose samples yielded a high *COX2* level (i.e., higher than *RPLP0*) (Table 4). The correlation coefficient between *COX2* expression and the number of alcoholic drinks consumed per week by the subject was also statistically significant ($P=0.026$). In addition, regular aspirin users (3 or more times per week) were more common among subjects expressing *COX2* ($P=0.005$). Finally, there was a marginally significant correlation (Spearman correlation coefficient 0.366, $P=0.051$) between *EGFR* and *COX2* expression. None of these correlated with *ESR1* methylation.

Discussion

The present study demonstrates that fecal samples collected in a commercially available nucleic acid preservative are adequate for testing DNA methylation and gene expression. A recently invented device for participants to self-collect, preserve, and mail fecal samples safely was used reliably by more than 50 subjects. Moreover, significant correlations between expression of *EGFR* and *COX2* and various aspects of participants' medical histories, smoking, and alcohol use were observed.

ESR1 was chosen for methylation analysis for healthy volunteers in this study, because its hypermethylation has been associated not only with colorectal tumors but also with aging^{9,24,25}. However, no association with age was observed in our study. This may reflect the relatively narrow age range of our subjects since our study population consisted of individuals generally recommended for colorectal cancer screening. Because of this study design, all subjects were between 48 and 73 years old, except for one subject who was 27 years old but had a history of polyps. Alternatively, as most earlier reports were based on gastrointestinal disease or surgery clinics, age-related gastrointestinal pathologies may have confounded these associations with age. Studies have revealed that methylation status in specific gene promoters is affected by an assortment of environmental factors, but our study found little evidence of an effect of these environmental factors on *ESR1* promoter

methylation in exfoliated gastrointestinal cells. These discrepancies may arise from differences in tissues (normal vs tumor) and genes analyzed¹²⁻¹⁶.

EGFR is a member of the tyrosine kinase family of cell surface receptors that play key roles in regulating proliferation, differentiation and transformation of cells in many tissues. *EGFR* overexpression and increased tyrosine kinase activities have been associated with many malignancies including colorectal cancer²⁶ and its precursor lesions such as colorectal polyps, and ulcerative colitis²⁷. Thus, our observation that subjects reporting a history of colorectal polyps tended to exhibit higher *EGFR* expression in their exfoliated cells may have significant clinical implications. In addition, Brandt *et al.* reported that a polymorphic repeat sequence in the *EGFR* gene, leading to *EGFR* overexpression, was associated with a family history of cancer²⁸, consistent with our observation of a greater prevalence of a family history of colorectal cancer among individuals with higher *EGFR* expression. The finding that smoking was a negative predictor of *EGFR* expression is intriguing in view of growing observations that non-smokers are more responsive to anti-*EGFR* therapies for non-small cell lung cancer than smokers²⁹⁻³³. Non-smokers are also more likely to display *EGFR* activation³⁴ and mutations^{31,35-38} that lead to gene amplification and increased sensitivity to anti-*EGFR* agents^{39,40}, and increased gene copy numbers^{31,41}. Although the data specific to colorectal cancer outcome by smoking status are limited, the importance of *EGFR* copy number for clinical response to anti-*EGFR* treatment for colorectal cancer has previously been recognized⁴².

Increased *COX2* expression was associated with alcohol drinking and regular aspirin use in our study. The association with alcohol intake is intriguing, as alcohol intake has been convincingly associated with an increased risk of colorectal cancer, especially for men¹⁷. In support of this association, increased cell regeneration and proliferation has been observed in experimental animals treated with ethanol as well as in chronic alcoholic patients⁴³⁻⁴⁵. These effects of alcohol have been hypothesized to be mediated through prostaglandin production (via COX), lipid peroxidation, generation of reactive oxygen species, and proinflammatory cytokine induction^{17,46,47}. The increase in *COX2* expression among regular aspirin users was unexpected. However, since aspirin inhibits *COX2* activity at a post-translational level²⁰, aspirin may drive gene expression in a compensatory fashion if there is an underlying disease leading to regular aspirin use. Because of the widespread use of this class of medications, caution should be exercised in evaluating *COX2* expression data as a potential marker for colorectal cancer screening¹⁰.

This study has several limitations. First, we are fully aware that the sample size of this study is small and thus relates the low statistical power for detecting a modest effect size. Inadequate statistical power may also account for the lack of an observed statistical association between the extent of *ESR1* methylation and covariates studied. On the other hand, there is a high likelihood that some of the associations observed in this study were chance findings due to multiple comparisons. Apparently, the associations found in our study need to be confirmed with larger samples as well as in independent populations. In fact, this study was designed to serve as a pilot to develop methodology for larger population studies.

Second, only 2 colonies were cloned for quantifying the degree of *ESR1* methylation for each subject. Analysis of more colonies per sample could have more accurately reflected quantitative changes in a larger number of exfoliated cells. Furthermore, although DNA and RNA preservation and extraction methods were adequate to obtain measurements for most subjects, some degradation did still occur, and this could be improved. In the present study, several adjustments were important for ensuring the success of our analyses. For instance, for DNA methylation analysis, we found that amplifications were more robust and reproducible targeting sequences of 300 bp or shorter (data not shown). This constrained choices of CpG islands. The bisulfite sequencing protocol is also highly labor intensive. For further studies on genes more closely related to colorectal cancer, higher throughput methods, e.g., Taqman quantitative methylation-specific PCR, pyrosequencing, and MALDI-TOF^{48,49}, need to be developed. To compensate for low yields of human RNA, samples were subjected to a pre-amplification process after reverse transcriptase reactions. The use of different RNA pre-amplification technologies⁵⁰ may maximize the potential of these degraded samples.

Finally, our data concerning family history and history of polyps were self-reported, not confirmed by medical records. Thus, a certain degree of misclassification of family history may be present⁵¹. In addition, polyps could not be histologically defined and thus included hyperplastic polyps beside adenoma, although these polyps have been acknowledged as a high risk lesion for colorectal cancer⁵².

In conclusion, the present study demonstrates that simultaneous analyses for DNA and RNA markers are feasible in stool samples treated with a single type of nucleotide preservatives. This also provides promising information to advance the use of stool markers for identifying or monitoring high-risk individuals and for early detection of colorectal cancer. Specifically, *EGFR* expression in exfoliated cells in stool samples deserves further investigation as a potential target for colorectal cancer screening, while caution should be exercised in interpreting the data on *COX2* expression. Larger studies are warranted to confirm some of the observed associations.

Acknowledgments

This research was supported by the Research Enhancement Program of Wayne State University. The authors thank Ms Ann Bankowski for study subject enrollment and for data and sample collection, and Ms Christina Haska for technical assistance in the development of methylation assays.

References

1. Iyengar V, Albaugh GP, Lohani A, Nair PP. Human stools as a source of viable colonic epithelial cells. *FASEB J.* 1991; 5:2856–2859. [PubMed: 1655550]
2. Desilets DJ, Davis KE, Nair PP, Salata KF, Maydonovitch CL, Howard RS, Kikendall JW, Wong RK. Lectin binding to human colonocytes is predictive of colonic neoplasia. *Am J Gastroenterol.* 1999; 94:744–750. [PubMed: 10086661]
3. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: Molecular approaches. *Gastroenterology.* 2005; 128:192–206. [PubMed: 15633136]
4. Davis CD. Use of exfoliated cell from target tissues to predict responses to bioactive food components. *J Nutr.* 2003; 133:1769–1772. [PubMed: 12771314]

5. Yu Y, Majumdar APN, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I. Exfoliated cells in stool: A source for RT-PCR based analysis of biomarkers of gastrointestinal cancer. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:455–458. [PubMed: 18268130]
6. Nechvatal JM, Ram JL, Basson MD, Namprachan P, Niec SR, Badsha KZ, Matherly LH, Majumdar AN, Kato I. Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces. *J Microbiol Methods.* 2008; 72:124–132. [PubMed: 18162191]
7. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S, Shuber A. Improved fecal DNA test for colorectal cancer screening. *Clin Gastroenterol Hepatol.* 2007; 5:111–117. [PubMed: 17161655]
8. Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY, Sung JJ. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. *Am J Gastroenterol.* 2007; 102:1070–1076. [PubMed: 17378912]
9. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nat Genet.* 1994; 7:536–540. [PubMed: 7951326]
10. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. *Gastroenterology.* 2004; 127:422–427. [PubMed: 15300574]
11. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. Molecular determinants of cetuximab efficacy. *J Clin Oncol.* 2005; 23:3536–3544. [PubMed: 15908664]
12. Van Engeland M, Weijenberg MP, Roemen GMJM, Brink M, de Bruine AP, Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AFPM, Herman JG. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands Cohort Study on Diet and Cancer. *Cancer Res.* 2003; 63:3133–3137. [PubMed: 12810640]
13. Zochbauer-Muller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, Minna JD, Gazdar AF. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. *Int J Cancer.* 2003; 107:612–616. [PubMed: 14520700]
14. Wong TS, Man MWL, Lam AKY, Wei WI, Kwong YL, Yuen APW. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. *Eur J Cancer.* 2003; 39:1881–1887. [PubMed: 12932666]
15. Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, Lubet RA. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. *Carcinogenesis.* 2004; 25:1917–1923. [PubMed: 15205357]
16. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. *Int J Cancer.* 2003; 103:153–160. [PubMed: 12455028]
17. WCRF/AICR: 4.8 Alcoholic drinks. Food, nutrition, physical activity and the prevention of cancer: a global perspective. AICR; Washington DC: 2007. p. 157-171.
18. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA.* 2008; 300:2765–2778. [PubMed: 19088354]
19. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. *Gastroenterology.* 2008; 134:388–395. [PubMed: 18242207]
20. IARC: IARC handbooks of cancer prevention. Non-steroidal anti-inflammatory drugs. Vol. 1. IARC; Lyon: 1997.
21. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. *Diagn Mol Pathol.* 2005; 14:183–191. [PubMed: 16106201]

22. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev.* 2006; 15:1115–1119. [PubMed: 16775168]
23. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, Schroy PC 3, Sontag S, Johnson D, Markowitz S, Paszat L, Berger BM. A simplified, noninvasive stool DNA test for colorectal cancer detection. *Am J Gastroenterol.* 2008; 103:2862–2770. [PubMed: 18759824]
24. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. *Cancer Res.* 2001; 61:3573–3577. [PubMed: 11325821]
25. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. *Br J Cancer.* 2006; 94:593–598. [PubMed: 16421593]
26. Khazaie K, Schirmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. *Cancer Metastasis Rev.* 1993; 12:255–274. [PubMed: 8281612]
27. Malecka-Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar APN. Differential activation of total and EGF receptor tyrosine kinase in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. *Hepatogastroenterology.* 1997; 44:435–440. [PubMed: 9164515]
28. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J. J Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. *Cancer Res.* 2004; 64:7–12. [PubMed: 14729599]
29. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. *J Clin Oncol.* 2004; 22:1103–1109. [PubMed: 15020612]
30. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. *N Engl J Med.* 2005; 353:1331–1344.
31. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst.* 2005; 97:643–655. [PubMed: 15870435]
32. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. *Ann Oncol.* 2005; 16:1334–1342. [PubMed: 15956035]
33. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA. National Cancer Institute of Canada Clinical Trials Group: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR. 21. *Clin Lung Cancer.* 2006; 7:389–394. [PubMed: 16800964]
34. Zheng Z, Bepler G, Cantor A, Haura EB. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. *Chest.* 2005; 128:308–316. [PubMed: 16002951]
35. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki Y, So T, Nakata S, Morita M, Yasumoto K. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. *Br J Cancer.* 2006; 94:896–903. [PubMed: 16552419]
36. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. *Cancer Genet Cytogenet.* 2007; 173:107–113. [PubMed: 17321325]
37. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambila E, Hainaut P. Patterns of EGFR, HER2, TP53, and KRAS

- mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. *Cancer Res.* 2007; 67:5667–5672. [PubMed: 17575133]
38. Na II, Rho JK, Choi YJ, Kim CH, Park JH, Koh JS, Ryoo BY, Yang SH, Lee JC. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. *Lung Cancer.* 2007; 57:96–102. [PubMed: 17337084]
 39. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. *Oncol Rep.* 2007; 17:319–323. [PubMed: 17203167]
 40. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A.* 2004; 101:13306–13311. [PubMed: 15329413]
 41. Jeon YK, Sung SW, Chung JH, Park WS, Seo JW, Kim CW, Chung DH. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. *Lung Cancer.* 2006; 54:387–398. [PubMed: 17011067]
 42. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardeli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. *Lancet Oncol.* 2005; 6:279–286. [PubMed: 15863375]
 43. Seitz, HK.; Simanowski, UA. Cell turnover in the gastroin-testinal tract and the effect of ethanol. In: Preedy, VR.; Watson, RR., editors. *Alcohol and the gastrointestinal tract.* CRC Press; Boca Rato, FL: 1996. p. 273-287.
 44. Simanowski UA, Homann N, Knühl M, Arce L, Waldherr R, Conradt C, Bosch FX, Seitz HK. Increased rectal cell proliferation following alcohol abuse. *Gut.* 2001; 49:418–422. [PubMed: 11511565]
 45. Vincon P, Wunderer J, Simanowski UA, Koll M, Preedy VR, Peters TJ, Werner J, Waldherr R, Seitz HK. Inhibition of alcohol-associated colonic hyperregeneration by alpha-to-copherol in the rat. *Alcohol Clin Exp Res.* 2003; 27:100–106. [PubMed: 12544013]
 46. Amin PB, Diebel LN, Liberati DM. The intestinal epithelial cell modulates the effect of alcohol on neutrophil inflammatory potential. *J Trauma.* 2007; 63:1223–1229. [PubMed: 18212642]
 47. Fleming S, Toratani S, Shea-Donohue T, Kashiwabara Y, Vogel SN, Metcalf ES. Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. *Alcohol Clin Exp Res.* 2001; 25:579–589. [PubMed: 11329499]
 48. Shames DS, Minna JD, Gazdar AF. Methods for detecting DNA methylation in tumors: from bench to bedside. *Cancer Lett.* 2007; 251:187–198. [PubMed: 17166656]
 49. Ho SM, Tang WY. Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal- based adult diseases. *Reprod Toxicol.* 2007; 23:267–282. [PubMed: 17317097]
 50. Coudry RA, Meireles SI, Stoyanova R, Cooper HS, Carpino A, Wang X, Engstrom PF, Clapper ML. Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. *J Mol Diagn.* 2007; 9:70–79. [PubMed: 17251338]
 51. Soegaard M, Jensen A, Frederiksen K, Høgdall E, Høgdall C, Blaakaer J, Kjaer SK. Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. *Cancer Causes Control.* 2008; 19:469–479. [PubMed: 18197461]
 52. Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon SJ, Yeoh KG, Goh KL, Solano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK. Asia Pacific Working Group on Colorectal Cancer: Asia Pacific consensus recommendations for colorectal cancer screening. *Gut.* 2008; 57:1166–1176. [PubMed: 18628378]

Figure 1.

A) CpG island analyzed in this paper. The 27 potentially methylated CpG sites in the 5'-untranslated genomic sequence of *ESR1* are highlighted and underlined. The italic *ATG* is the translation start codon of the gene. B) Methylation at the 27 loci illustrated in 1A for 2 clones of DNA sequences derived from each of 49 subjects. Symbols indicate a methylated CpG; blanks denote no methylation.

Table 1
Numbers of study subjects included and median and range of the test results for each marker

Markers	No. tested	No. failed	Effective sample size	No. with undetectable levels	Median *	Range of detectable levels *
<i>ESR1</i> methylation	52	3	49	14	1.5	0.5 - 27.0
<i>EGFR</i> expression	31	2	29	2	0.556	-2.398-4.143
<i>COX2</i> expression	31	2	29	10	-0.942	-3.049-4.874
Total	56		55	(Age 27-73, median 60 years, 53% male)		

* Values are expressed as the number of detected methylation sites out of the 27 loci for *ESR1* and differences in threshold cycle numbers (Ct values) from a housekeeping gene for *EGFR* and *COX2*.

Table 2
Prevalence (%) of selected characteristics among 49 subjects according to *ESR1* promoter methylation status

Characteristics	Definition	<i>ESR1</i> methylation*			<i>P</i> value for Fisher's exact test	<i>P</i> value for Spearman correlation
		Negative (n = 17)	Low (n = 19)	High (n = 13)		
Age	60	58.8	47.4	53.9	0.826	0.274
Gender	Male	47.1	52.6	61.5	0.720	-
Cigarette smoking	Ever	47.1	57.9	46.2	0.817	-
	20 pack-years	29.4	26.3	15.4	0.707	0.574
Alcohol	1 drin k/day	52.9	47.4	53.9	1.000	0.678
Colorectal polyp		17.7	21.1	15.4	1.000	-
Family history of colorectal cancer		5.9	21.1	0.0	0.198	-
Regular aspirin use		47.1	26.3	38.5	0.459	-

* Negative <1, Low 1.0-9.5, High 10 methylated out of 27 CpG loci.

Table 3
Prevalence (%) of selected characteristics among 29 subjects according to *EGFR* expression levels

Characteristics	Definition	<i>EGFR</i> expression *			<i>P</i> value for Fisher's exact test	<i>P</i> value for Spearman correlation
		Low (n = 10)	Intermediate (n = 9)	High (n = 10)		
Age	60	40.0	55.6	30.0	0.575	0.873
Gender	Male	60.0	66.7	60.0	1.000	-
Cigarette smoking	Ever	90.0	66.7	40.0	0.066	-
	20 pack-years	40.0	33.3	10.0	0.344	0.046
Alcohol	1 drin k/day	40.0	55.6	50.0	0.897	0.066
Colorectal polyp		0.0	44.4	20.0	0.050	-
Family history of colorectal cancer		0.0	0.0	30.0	0.089	-
Regular aspirin use		30.0	33.3	30.0	1.000	-

* Low: negative or lower than a housekeeping gene, Intermediate: 0 to 1.5 Ct units greater expression, High: more than 1.5 Ct units greater expression than a housekeeping gene.

Table 4
Prevalence (%) of selected characteristics among 29 subjects according to COX2 expression levels

Characteristics	Definition	Cox2 expression [*]			P value for Fisher's exact test	P value for Spearman correlation
		Negative (n = 10)	Low (n = 9)	High (n = 10)		
Age	60	30.0	55.6	40.0	0.575	0.320
Gender	Male	69.7	55.6	60.0	0.893	-
Cigarette smoking	Ever	80.0	44.4	70.0	0.296	-
	20 pack-y ears	30.0	11.1	40.0	0.450	0.985
Alcohol	1 drink/day	30.0	33.3	80.0	0.061	0.026
Colorectal polyp		20.0	11.1	30.0	0.847	-
Family history of colorectal cancer		10.0	0.0	20.0	0.754	-
Regular aspirin use		0.0	66.7	30.0	0.005	-

^{*} Negative: no expression, Low: lower than a housekeeping gene, High: higher than a housekeeping gene.